secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001193125-23-198580
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies gets IDMC nod to continue REVEAL Phase 1/2 trial for TSHA-102 in Rett syndrome
--------------------------------------------------------------------------------

- IDMC recommended trial continuation after review of initial clinical data from first adult dosed with TSHA-102.
- Dosing of second patient expected in Q3 2023.
- Initial clinical update on first patient planned for Q2 2023 earnings call in mid-August.
- TSHA-102 is an AAV-based gene therapy for Rett syndrome due to MECP2 loss-of-function mutation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523198580/0001193125-23-198580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523198580/d535611d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-198580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer